Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,989 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer Disease Dementia Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The PorchLight Project

NCT05550727
View directory record Official record
Conditions
Memory Loss, Alzheimer Disease, Dementia
Interventions
PorchLight
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 15, 2026, 4:21 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

NCT06657768
View directory record Official record
Conditions
Alzheimer Disease, Healthy
Interventions
LY4006895, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
11
States / cities
Los Alamitos, California • Lady Lake, Florida • Maitland, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

NCT00440050
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
DHA (Docosahexaenoic Acid), Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
50 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Daridorexant to Prevent Delirium After Heart Surgery

NCT06630390
View directory record Official record
Conditions
POSTOPERATIVE DELIRIUM, POSTOPERATIVE COGNITIVE DECLINE
Interventions
Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

NCT03757325
View directory record Official record
Conditions
Alzheimer Disease
Interventions
DNL747, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00087789
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CERE-110: Adeno-Associated Virus Delivery of NGF
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Diego, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Not applicable Interventional

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

NCT03926520
View directory record Official record
Conditions
Alzheimer Dementia, Agitation,Psychomotor
Interventions
Electroconvulsive Therapy (ECT)
Device
Lead sponsor
Brent Forester
Other
Eligibility
40 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Belmont, Massachusetts • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Active, not recruiting Not applicable Interventional

Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies

NCT04699786
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
Arm A , Arm B, Arm C, & Arm D
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

NCT04100889
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 15, 2026, 4:21 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Core Center

NCT01421420
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Age-Related Memory Disorders
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
50 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 15, 2026, 4:21 PM EDT
Not yet recruiting Not applicable Interventional

Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias

NCT07839286
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment
Interventions
Jigsawdio Multisensory Puzzle Platform, Standard Jigsaw Puzzle Activity
Behavioral
Lead sponsor
Callahan-Young LLC DBA Jigsawdio
Industry
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03444870
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
33
States / cities
Tucson, Arizona • Irvine, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Metformin on AD Biomarkers

NCT01965756
View directory record Official record
Conditions
Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
Interventions
Metformin, Placebos
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 15, 2026, 4:21 PM EDT
Recruiting Phase 4 Interventional

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

NCT07695701
View directory record Official record
Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
Interventions
Acoramidis (AG10) oral tablet
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)

NCT00973518
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2010 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00556660
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] AV-151
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 15, 2026, 4:21 PM EDT
Completed No phase listed Observational

Equality in Caregiving: Facilitating Caregiver Mastery Among LGBT Caregivers of PLWD

NCT04394260
View directory record Official record
Conditions
Dementia, Caregiver Burnout
Interventions
Savvy Caregiver Program via Remote Learning, Focus group
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Supporting Our Caregivers In ADRD Learning (SOCIAL)

NCT06276023
View directory record Official record
Conditions
Alzheimer's Disease and Related Dementias, Quality of Life, Caregiver Stress
Interventions
Mindful and Self-Compassionate Care Program (MASC), Health Education Program (HEP)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

NCT03625622
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
AR1001, Placebo
Drug
Lead sponsor
AriBio Co., Ltd.
Industry
Eligibility
55 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Banning, California • Sacramento, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 15, 2026, 4:21 PM EDT
Enrolling by invitation Not applicable Interventional

TMS Pilot in Early AD II

NCT06817902
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Intermittent theta burst stimulation active coil, Sham coil
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)

NCT02534480
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
NGP 555
Drug
Lead sponsor
NeuroGenetic Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Passport to Brain Wellness in Sedentary Adults

NCT00979446
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Guided, Self-directed
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
60 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 15, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cardiac-Control Affecting Learning Through Mindfulness (CALM)

NCT06410157
View directory record Official record
Conditions
Age-related Cognitive Decline, Alzheimer Disease
Interventions
Daily practice
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Not yet recruiting Phase 2 Interventional

Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

NCT07781657
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RO7568282, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Laurelton, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 4:21 PM EDT